Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II T (Q38969672)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II T |
scientific article |
Statements
1 reference
Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II T (English)
1 reference
1 reference
Eleftherios P Mamounas
1 reference
John W Smith
1 reference
Marc E Buyse
1 reference
Priya Rastogi
1 reference
Charles E Geyer
1 reference
Samuel A Jacobs
1 reference
Erica J Patocskai
1 reference
André Robidoux
1 reference
Alison K Conlin
1 reference
Bilal Ansari
1 reference
George P Keogh
1 reference
Philip J Stella
1 reference
Howard M Gross
1 reference
Raymond S Lord
1 reference
Jonathan A Polikoff
1 reference
Celine Mauquoi
1 reference
Norman Wolmark
1 reference
28 July 2016
1 reference
1 reference
17
1 reference
1
1 reference
48-54.e3
1 reference
Identifiers
1 reference
1 reference